Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kowsar versus Genzyme anti-thymocyte globulin induction in adult kidney transplantation
IRCT20100127003200N6Phase 3Completed
- Sponsor
- Kowsar Biotechnology
- Start
- Apr 2019
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of antithymocyte globulin in kidney transplant (2 arms), sponsored by Kowsar Biotechnology. Primary endpoints: Any adverse drug outcome and reaction, Graft rejection and 4 more. Started Apr 2019; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
kidney transplant
Beyond the preview
Go deeper on IRCT20100127003200N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100127003200N6.